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Abstract
Gene-expression signature-based disease classification and clinical outcome prediction has not been widely introduced in
clinical medicine as initially expected, mainly due to the lack of extensive validation needed for its clinical deployment.
Obstacles include variable measurement in microarray assay, inconsistent assay platform, analytical requirement for
comparable pair of training and test datasets, etc. Furthermore, as medical device helping clinical decision making, the
prediction needs to be made for each single patient with a measure of its reliability. To address these issues, there is a need
for flexible prediction method less sensitive to difference in experimental and analytical conditions, applicable to each
single patient, and providing measure of prediction confidence. The nearest template prediction (NTP) method provides a
convenient way to make class prediction with assessment of prediction confidence computed in each single patient’s gene-
expression data using only a list of signature genes and a test dataset. We demonstrate that the method can be flexibly
applied to cross-platform, cross-species, and multiclass predictions without any optimization of analysis parameters.
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Introduction
It has been nearly a decade since genome-wide expression
profiling was applied on clinical specimens with a great expectation
for its potential to fish out disease-related genes as diagnostic
biomarkers and/or therapeutic targets in comprehensive and
unbiased manner [1]. Many studies have subsequently reported
sets of coordinately dysregulated genes, i.e., gene-expression
signature, correlated with clinical phenotype of interest. Some
studies also have shown that the signature could be more sensitive
than traditional histological assessment in monitoring biological
status of diseased tissue [2]. Accompanying these studies, consensus
on key issues of study design and analysis protocol emerged [3,4]
However, despite these efforts, most of these signatures have not yet
been introduced into clinical practice.
As a medical device utilized for clinical diagnostic and
prognostic prediction, the signatures need to be intensively
evaluated before their clinical deployment. However, this critical
process has been hampered by the following obstacles. First, it is
widely recognized that the measurement in gene-expression
microarray could vary across experimental conditions and assay
platforms [5,6], and it is still uncertain what the optimal and
sustainable assay platform is given the rapid genomics technology
development. Second, analytical restrictions such as requirements
for comparable pair of training and test datasets, specific analytic
algorithm and parameters used in the initial study, etc., often
preclude the opportunity of preclinical assessment of the signature.
Third, the signatures are often defined based on various types of
experimental techniques applied on variety of biomolecules or
even biological knowledge, which could be a valuable source of
potential biomarker. However, there is no established way to
utilized them for prediction analysis to estimate their potential
value in clinical practice. Furthermore, as a tool to help physicians’
clinical decision making, the prediction method should be
applicable to each single patient, although this is overlooked in
most of existing prediction methods, which were designed for a
dataset consisting of multiple samples [7]. In addition, it is ideal
that each prediction is accompanied with a measure of confidence
to enable more reliable clinical decision making.
Nearest template prediction (NTP) is a method designed to address
these issues, without requiring corresponding training dataset. It has
been successfully applied for gene-expression-based clinical classifica-
tion and outcome prediction [2,8,9]. In this article, we describe
detailed methodology of NTP and its performance in comparison with
other commonly used prediction methods to highlight its advantage.
Results
Overview of Nearest Template Prediction (NTP)
Diagnostic and/or prognostic genomic signature is usually a set
of genes coherently over- or under-expressed in patients with a
certain phenotype of interest, or combination of these sets of genes,
and assumed to indicate ON (or up) or OFF (or down) of relevant
biological functions. The major task of gene-expression signature-
based class prediction method would be simply to capture the
presence or absence of these patterns in each sample, rather than
recapitulating complex combinatorial pattern of the signature gene
expression. NTP is a simple, hence flexible, nearest neighbor-
based method designed to capture such information. It requires
only a list of signature genes and a dataset to be tested.
Methodological details are described in the Materials and
Methods section and Figure 1. Here we overview the key steps:
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signature genes (template)
For simplicity, suppose the case of prediction of 2 subclasses, A
and B. The signature genes consist of nA (marker.A) and nB (marker.B)
over-expressed marker genes in subclass A and B, respectively. In a
hypothetical subclass A sample, it is supposed that marker.A are
coherently over-expressed and marker.B are under-expressed. If the
expression level of each signature gene is standardized, genes in
marker.A are expected to show uniformly high, and genes in
marker.B are expected to show uniformly low expression. The
expression pattern of the signature in a subclass B sample is
similarly assumed. These expression patterns of hypothetical
samples representing the subclasses are used as templates for the
prediction. Specifically, a value of 1 is assigned to marker.A and 21
is assigned to marker.B for the template of subclass A (template.A).
The template of subclass B (template.B) is similarly defined.
Step 2: Find nearest template to assign a prediction label
to a test sample
Suppose N genes are measured in a microarray experiment for a
test sample S (N$nA+nB). Expression levels of the nA+nB signature
genes (marker.A and marker.B) are extracted from the N genes
(sample.signature). Subsequently, proximity of sample.signature to
template.A or template.B is calculated as distance d using cosine
distance (default). If the distance to template.A is smaller, a
prediction of ‘‘subclass A’’ is assigned to sample S. A prediction
of ‘‘subclass B’’ is similarly performed.
Step 3: Compute prediction confidence
Significance for the prediction is compued as a nominal p-value
estimated based on a null distribution for the distance d to the
templates generated by randomly resampling nA+nB genes from the
N genes 1,000 times (default). This computation is performed
within the data of sample S and does not use data of other samples
in the test dataset. When prediction analysis is performed for
multiple samples ($2), one might want to correct the set of
prediction confidence p-values for multiple hypothesis testing. In
this article, we used false discovery rate (FDR),0.05 for the
criteria of high-confident prediction.
NTP can be flexibly applied to prediction of clinical disease
subtypes (Example 1), cross-platform prediction of molecular
disease subtype (Example 2), cross-species phenotype prediction
(Example 3), and multiclass (.2 classes) prediction (Example 4)
without any special optimization of analytical parameters.
Furthermore, we demonstrate that NTP performs reasonably well
in predicting molecular subclasses in real-world, large-scale
datasets of breast cancer (Example 5). (See Table 1 for the
details of each dataset.)
Example 1. Prediction of acute lymphoblastic leukemia
(ALL) and acute myeloid leukemia (AML)
First, we applied NTP for prediction of the major leukemia
subtypes, ALL and AML [10] as a straightforward 2-class
prediction problem in comparison with other commonly used
methods: classification and regression tree (CART), weighted
voting (WV), support vector machine (SVM), and k-nearest
neighbor (kNN). We evaluated a 35-gene signature reported in
the original publication in the test set including 35 patients
(Table 1). Prediction error rate was comparable to other methods
and even lower in the samples with high prediction confidence
(FDR,0.05) (Table 2). Samples receiving low prediction
confidence (FDR$0.05) showed no obvious high expression of
either of ALL or AML marker genes, and more number of
inconsistent predictions across the different prediction methods
were observed in these samples (Figure 2, Table 3).
Figure 1. Methodology of Nearest Template Prediction (NTP). Based on predetermined gene signature of subclasses A and B including nA
over-expressed genes in subclass A (marker.A) and nB over-expressed genes in subclass B (marker.B), template.A and template.B are defined as
representative expression pattern of the signature genes for each subclass (Templates of subclass A and B). From microarray data measuring N genes
in sample S (Microarray data of sample S), the nA+nB signature genes are extracted (Signature in sample S: sample.signature), and its proximity to the
templates is evaluated by calculating distance d. The label of closer template is assigned as a prediction for sample S, and its significance is estimated
as a nominal p-value based on a null distribution for d generated by randomly resampling nA+nB genes from the N genes 1,000 times. Red and blue
colors in heatmaps indicate high and low gene expression, respectively.
doi:10.1371/journal.pone.0015543.g001
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receptor (ER) positivity in breast cancer
We next tested NTP in the setting of cross-platform prediction
analysis. The ER positivity signature, which consists of 202 up-
regulated and 552 down-regulated genes, was defined in the
training set of 97 samples [11], and assessed on the test set of 49
samples [12] (Table 1, Figure 3). Again, prediction errors and
inconsistent predictions across different methods accumulated
within the samples with low prediction confidence (FDR$0.05)
(Table 2 and 3).
Example 3. Cross-species prediction of liver cirrhosis
between human and rat
In this example, we evaluated NTP’s prediction performance in
cross-species prediction. We first defined a human liver cirrhosis
signature including 801 up-regulated and 445 down-regulated
genes in comparison between 13 cirrhotic and 10 normal livers
from publicly available dataset [13] (Table 1). We then tested
whether the signature was presented in another publicly available
dataset of gene-expression profiles of rat liver cirrhosis induced by
bile duct ligation. NTP made highly confident prediction
(FDR,0.05) for all samples with no error and showed no
inferiority to other methods (Figure 4, Table 2 and 3).
Example 4. Prediction of multiple tissue types
All the previous examples demonstrated the predictive perfor-
mance in simple 2-class prediction. This example is to assess NTP
in multi-class (.2 classes) prediction. A gene-expression signature
predicting 4 different tissue types (breast, prostate, lung, and colon)
was determined in the training set (N=51) and evaluated in the
test set (N=52) (Table 1) [14,15]. The signature includes 4
groups of significantly over-expressed genes in each tissue type in
comparison to the rest (Breast: 388 genes, Prostate: 667 genes,
lung: 174 genes, and colon: 374 genes). In this setting of multi-class
prediction, NTP again demonstrated high-confident prediction
(FDR,0.05) for all samples without making error (Figure 5,
Table 2 and 3).
Example 5. Prediction of breast cancer molecular
subclass
Lastly, we analyzed multiple large scale datasets of breast cancer
as an example of molecular subclass prediction in real-world
clinical samples. Signature genes of the 5 subclasses (Basal-like,
HER2, Luminal A, Luminal B, and Normal breast-like) were
defined in the largest dataset (N=295) [16] based on prediction
Table 1. Datasets.
Example No. of samples Assay platform Source of dataset Reference
1. ALL vs. AML Training set 38 HuGeneFL* (a) [10]
Test set 35 HuGeneFL* (a) [10]
2. ER positivity in breast cancer Training set 97 Hu25K** (b) [11]
Test set 49 HuGeneFL* (a) [12]
3. Liver cirrhosis in human and rat Training set 23 HG-U133plus2* GSE6764 [13]
Test set 12 Rat Genome 230* GSE13747 -
4. Multiple tissue types (breast, lung, prostate, colon) Training set 51 HG-U95A* (a) [14,15]
Test set 52 HG-U95A* (a) [14,15]
5. Molecular subclasses of breast cancer Training set 295 Stanford cDNA (c) [16]
Test set 1 (‘‘TransBig’’) 198 HG-U133A* GSE7390 [18]
Test set 2 (‘‘Wang’’) 286 HG-U133A* GSE2034 [19]
Test set 3 (‘‘Weigelt’’) 53 Human WG6*** E-TABM-543 [17]
ALL: acute lymphoblastic leukemia, AML: acutr myeloid leukemia, ER: estrogen receptor, GSE: NCBI’s Gene Expression Omnibus accession ID (www.ncbi.nlm.nih.gov/
geo/).
E-TABM: EBI’s Array Express accession ID (www.ebi.ac.uk/arrayexpress/).
(a) www.broad.mit.edu/cgi-bin/cancer/datasets.cgi.
(b) www.rii.com/publications/default.htm.
(c) microarray-pubs.stanford.edu/wound_NKI/explore.html.
All datasets used for the analysis are available as Supporting Information.
Microarrays manufactured by *Affymetrix (Santa Clara, CA), ** Agilent Technologies (Palo Alto, CA), or ***Illumina (San Diego, CA).
doi:10.1371/journal.pone.0015543.t001
Table 2. Summary of prediciton error rates according to
prediction method.
Example CART WV SVM k-NN NTP
NTP
(FDR,0.05)
#1 9 %3 % 9 %6 %1 1 % 0 %
#2 8% 14% 20% 12% 10% 5%
#3 0% 17% 0% 17% 0% 0%
#4 31% -* 2% 6% 0% 0%
#5 (test set 1) 47% -* 30% 47% 42% 42%
#5 (test set 2) 37% -* 27% 44% 31% 28%
#5 (test set 3) 40% -* 26% 23% 32% 17%
CART: classification and regression tree, WV: weighted voting, SVM: support
vector machine, k-NN: k-nearest neighbor, NTP: nearest template prediction,
FDR: false discovery rate.
*WV is designed only for 2-class prediciton.
In Example #5, prediction error indicates inconsistency with prediciton made
with ‘‘Sorlie2003 SSP’’ predictor [17].
doi:10.1371/journal.pone.0015543.t002
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evaluated in 3 datasets of independent patient series generated on
various microarray platforms [17–19] (Table 1). The signature
consists of over-expressed genes in each subclass (Basal-like: 956
genes, HER2: 125 genes, Luminal A: 387 genes, Luminal B: 291
genes, and Normal breast-like: 134 genes). We asked whether NTP
and other prediction methods could reproduce the prediction
reported in the original publication (Figure 6). The prediction
error rate was not inferior to those of other methods (Table 2),
and consistency of prediction across the methods was higher in
samples with high prediction confidence (FDR,0.05) (Table 3).
In the original publication by Weigelt et al., 3 different SSP models
were compared and yielded averaged error rates of 40%, 38%,
and 38% in Test set 1, 2, and 3, respectively [17], which are
comparable or even worse compared to the results of NTP
(Table 3).
Discussion
In gene-expression microarray analysis, signature-based ap-
proach, in contrast to single gene-based approach, has been
successfully utilized for robust identification of molecular pathway
activation, prediction of disease phenotype and outcome, moni-
toring of response to genetic or pharmacologic experimental
perturbations [2,10,20–22]. These examples of success seem to be
achieved particularly because the signature genes exhibit coher-
ently similar expression pattern, and missing or failed measure-
ments from some of the signature genes (due to malfunctioning
probe, genetic polymorphism at probed site, etc.) could be
compensated by rest of the genes in capturing the same trend of
biological dysregulation. By focusing on such direction of
expression change measured by similarly behaving multiple genes,
the analysis may become less affected by difference in experimen-
tal condition and assay platform. NTP was intended to capture
such direction of expression change of the signature genes, in the
modeling of the templates. Our examples clearly showed that the
method works reasonably well in prediction of 2 or more classes
beyond different assay platforms and species without necessity of
any special analysis parameter optimization. In general, no specific
prediction algorithm universally outperforms others (so called no
free lunch theorem), but it would worth to note that NTP showed
constantly low error rate in predictions with high confidence.
In gene-expression profiling studies utilizing clinical specimens,
it is frequently noticed that a certain proportion of samples do not
Figure 2. Example 1: Prediction of acute lymphoblastic
leukemia (ALL) and acute myeloid leukemia (AML). Previously
reported ALL-AML signature was evaluated on the test set (N=35)
employed in the study. Samples are ordered according to proximity to
either of the template of ALL or AML to visualize clear or unclear
expression pattern of the signature genes in each sample. Note that
closer distance to template (i.e., most left or right in heatmap) does not
necessarily indicate higher prediction confidence because the confi-
dence p-value is calculated based on null distribution for the distance
generated for each individual sample. CART: classification and
regression tree, WV: weighted voting, SVM: support vector machine,
kNN: k-nearest neighbor, FDR: false discovery rate.
doi:10.1371/journal.pone.0015543.g002
Table 3. Prediciton results according to prediction confidence.
Example % samples with FDR,0.05 Error rate Consistency across prediction methods
FDR,0.05 FDR$0.05 FDR,0.05 FDR$0.05
#1 49% 0% 22% 88% 78%
#2 88% 9% 50% 86% 17%
#3 1 0 0 % 0 %- * 0 %- *
#4 100% 0% -* 63% -*
#5 (test set 1) 97% 42% 67% 38% 0%
#5 (test set 2) 90% 28% 64% 36% 4%
#5 (test set 3) 57% 17% 52% 50% 26%
FDR: false discovery rate.
*No sample received NTP prediciton with FDR$0.05.
In Example #5, prediction error indicates inconsistency with prediciton made with ‘‘Sorlie2003 SSP’’ predictor [17].
doi:10.1371/journal.pone.0015543.t003
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characteristic to the subclasses. In fact, we observed such samples
in the middle of the heatmap in Example 1 and 2 lacking obvious
high expression of ALL/AML or ER signature genes (Figure 2
and 3). We observed that the discordant predictions between
different methods tended to accumulate within these samples,
suggesting that such discordance occured due to the vague
expression pattern rather than superiority of certain prediction
algorithm.
The vague expression pattern may not be a problem in
understanding biological nature of gene-expression signature in a
set of multiple samples as long as a subset of samples presents
distinct expression pattern of the signature. However, if the
signature is intended to be used as a clinical diagnostic or prognostic
tool, the assay and prediction need to be performed on a single
patient basis. And assessment of prediction confidence is necessary
to make reliable clinical decision considering any classification and
prediction algorithms could assign predicted class labels even in
randomly generated data. Some existing prediction methods assign
prediction class label and/or prediction confidence according to
relative expression of signature genes within a given collection of
samples, i.e., these methods merely split the dataset into equal-sized
subsets using a cut-off such as median specific to the sample
collection, therefore each prediction could be changed according to
which samples areincluded inthe collection [7,23,24].Weigelt et al.
reported a method assigning prediction foreachsingle patient based
on correlation to ‘‘centroid’’ (a vector of mean expression levels of
signature genes calculated for each subclass in training set) [17].
However, the criteria of ‘‘unclassifiable’’ sample (correlation
coefficient ,0.1) is arbitrary, and the performance of ‘‘centroid’’
might be affected when the numerical values in the vector of
‘‘centroid’’ overfit training set and if substantial cross-platform
difference exists in test set.
In actual clinical setting, it is possible that molecular subclasses
are presented in imbalanced manner across patient populations. In
fact, in Example 5, some subclasses are underrepresented or even
does not exist in some patient series. Even in such situation, NTP
showed reasonable predictive performance constantly comparable
or not inferior to other methods, supporting its usefulness as a
clinical tool.
NTP is a convenient method, which allows flexible assessment
of any existing gene signatures across wide variety of patient
populations, assay platforms, and even species even if there is no
corresponding training dataset. It will facilitate extensive preclin-
ical evaluation of existing genomic signatures for their potential
value as reliable medical diagnostics. The NTP methodology
is implemented as Nearest Template Prediction module of
GenePattern analysis toolkit and publicly available from www.
broadinstitute.org/genepattern.
Materials and Methods
Data preprocessing
We utilized data sets already normalized in the respective
studies. Multiple probes corresponding a single gene were
summarized into a gene symbol provided by NBCI Entrez Gene
Figure 3. Example 2: Cross-platform prediction of estrogen
receptor (ER) positivity in breast cancer. The ER signature was
defined and tested on a pair of independent training (N=97) and test
(N=49) datasets generated on different microarray platforms (see
Table 1 for details). Samples are ordered according to proximity to
either of the template of ER (+)o rE R( 2).
doi:10.1371/journal.pone.0015543.g003
Figure 4. Example 3: Cross-species prediction of liver cirrhosis
between human and rat. Human liver cirrhosis signature generated
by comparing 13 cirrhotic and 10 normal livers was tested on rat livers
with or without liver cirrhosis induced by bile duct ligation.
doi:10.1371/journal.pone.0015543.g004
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signal intensities. Rat genes were converted into orthologous
human genes by using a mapping table provided by the Jackson
laboratory (http://www.informatics.jax.org/).
To capture ‘‘up’’ or ‘‘down’’ regulation of signature genes
modeled as the template, dynamic range of measurement for each
gene probe is standardized to be similar or comparable across gene
probes on the microarray. Once clinical deployment platform is
decided, the assay is assumed to be calibrated to generate
reproducible measurements and a set of reference samples is run
to test its validity. This reference dataset will allow to calculate
sample-wise mean and sample standard deviation for each gene
probe, which can be used for the standardization of each single
patient’s data obtained in actual clinical practice. NTP can take
vectors of the mean and sample standard deviation provided
separately from input dataset for the standardization (supported in
the R code packaged in the GenePattern NTP module).
Alternatively, when such reference dataset does not exist and a
research-level dataset is the only available material, NTP also can
use the input dataset to calculate the mean and sample standard
deviation for the standardization (current default of the Gene-
Pattern module).
Methodology of Nearest Template Prediction (NTP)
(i) Representative expression pattern of the signature
genes (template). Suppose the case of prediction of 2
subclasses, A and B, and the signature to be tested includes nA
and nB over-expressed marker genes in subclass A and B,
respectively. The template of subclass A (template.A) is defined as
a vector containing nA+nB elements: first nA elements correspond
over-expressed genes in subclass A (marker.A), and next nB elements
correspond over-expressed genes in subclass B (marker.B). To model
representative expression pattern of subclass A, i.e., over-
expression of marker.A and under-expressed of marker.B, a value
of 1 is assigned to each of the nA marker.A genes, and a value of 21
to each of the nB marker.B genes. The template of subclass B
(template.B) is similarly defined. In case of prediction of more than 2
subclasses, a value of 1 is assigned to subclass A marker genes and
a value of 0 is assigned to marker genes of the rest of subclasses.
Numerical values like t-statistic, signal-to-noise ratio, fold change,
or p-value, which is often reported together with list of signature
genes, can be used to weigh each gene to incorporate information
of its relative importance in the signature.
(ii) Nearest template to assign a prediction label to a test
sample. For a test sample, actual expression levels of the nA+nB
signature genes are extracted from N genes measured in the
microarray assay (N$nA+nB) to create a vector with nA+nB elements
(sample.signature). Proximity of sample.signature to template.A or
template.B is computed as distance d using cosine distance
(default) or Pearson correlation coefficient. Any other distance
measure can be used. If d to template.A is smaller than that to
template.B, a prediction label of subclass A is assigned to the test
sample, and a prediction of subclass B is similarly performed.
(iii) Prediction confidence (p-value). For the single test
sample, significance of the proximity to template is estimated as a
nominal p-value based on a null distribution for the distance d
generated by randomly resampling nA+nB genes from the N genes
multiple times (default is 1,000 times). Here, the null hypothesis is
that the signature genes show similar expression pattern to neither
of the templates, and the alternative hypothesis is that the
signature genes show similar expression pattern to any one of the
templates. A nominal p-value is computed based on the rank of
actual d in the null distribution. In case the prediction is made for a
set of multiple samples ($2), user can choose to correct the
p-values for multiple hypothesis testing using either false discovery
rate (FDR) [25] or Bonferroni correction.
Prediction analysis in each example
In Example 1, the list of signature genes reported in the
original publication was directly used for NTP, including 19 up-
regulated (GOLUB_ALL_VS_AML_UP) and 16 down-regulated
(GOLUB_ALL_VS_AML_DN) genes in ALL compared to AML
samples deposited in Molecular Signature Database (MSigDB)
(http://www.broadinstitute.org/msigdb/). The signature genes In
Example 2,5 were defined by random permutation-based t-test
implemented in Comparative Marker Selection module of
GenePattern analysis toolkit [26] (www.broadinstitute.org/gene-
pattern) with a significance threshold of FDR,0.05 (Example
2,4) or FDR,0.001 (Example 5). In multi-class (.2 classes)
prediction (Example 4 and 5), the signature was defined as a
concatenation of over-expressed genes in each class in comparison
to the rest. Genes significantly over-expressed in multiple classes
were removed from the signature. In Example 4, the dataset
including 4 tissue types (breast, prostate, lung, and colon) was
randomly split into training (N=51) and test (N=52) sets using
Split Dataset Train Test module of GenePattern.
Prediction analysis with other methods
Additional prediction analyses were performed within the same
signature gene space by using CART, WeightedVoting, SVM, and
KNN modules implemented in GenePattern with default analysis
parameters. For cross-platform (Example 2 and 5) and cross-
species (Example 3) predictions, each gene’s expression level was
Figure 5. Example 4: Prediction of multiple tissue types.
A signature distinguishing 4 tissue types (breast, prostate, lung,
and colon) was defined in the training set (N=51) and
evaluated on the test set (N=52). The signature was defined as
a concatenation of over-expressed genes in each tissue type in
comparison to the rest.
doi:10.1371/journal.pone.0015543.g005
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deviation in each dataset to adjust range of gene expression level
between training and test datasets. All datasets and class labels
used for the analysis are publicly available at http://www.
broadinstitute.org/cgi-bin/cancer/datasets.cgi.
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